NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

Disable ads (and more) with a membership for a one time $4.99 payment

Ace your North American Pharmacist Licensure Examination (NAPLEX) with our comprehensive practice test. Features include interactive flashcards, multiple-choice questions, with detailed hints and explanations. Fast-track your pharmacy career today!

Practice this question and more.

What is a specified risk when using the treatment for Cytomegalovirus (CMV) in severely immunocompromised states?

Hyperglycemia
Myelosuppression
Hepatotoxicity
Cardiotoxicity

The correct answer is: Myelosuppression

A While hyperglycemia is a possible side effect of the treatment for CMV, it is not considered a specified risk. It may occur in patients with pre-existing diabetes or in patients with glucose intolerance. B: Myelosuppression, a decrease in the production of blood cells, is a specified risk when using the treatment for CMV in severely immunocompromised states. This can lead to an increased risk of infection, anemia, and bleeding. C: Hepatotoxicity, or liver damage, can occur as a result of the treatment for CMV, but it is not considered a specified risk. It may be more common in patients with underlying liver disease. D: Cardiotoxicity, or damage to the heart muscle, is a potential side effect of the treatment for CMV, but it is not considered a specified risk. It may occur in patients with pre-existing heart conditions.